Literature DB >> 2784162

Neutralizing antibody and clinical status of human immunodeficiency virus (HIV)-infected individuals.

D R Alesi1, F Ajello, G Lupo, F Vitale, M Portera, F Spadaro, N Romano.   

Abstract

An assay based on inhibition of cytopathic effect of human immunodeficiency virus (HIV) strains in Molt 4 cells was developed to quantitate neutralizing antibodies (NA) in sera of HIV-infected individuals. The assay was specific and gave results comparable to those obtained by the inhibition of immunofluorescence (IFI) and reverse transcriptase (RT) activity. Attempts were made to correlate the presence and the antibody titres with the clinical status of HIV-infected individuals classified according to Walter Reed staging classification scheme. NA titres correlated inversely with the stage of HIV infection: Compared with acquired immunodeficiency syndrome (AIDS) patients, HIV-infected subjects at stage WR1 had significantly higher NA titres. Moreover, a decrease in NA titre in relation to clinical deterioration was noted in sequential sera of eight of 11 AIDS patients, retrospectively examined, for NA. The symptomless subjects showed either the same level of NA or a trend towards an increasing antibody titre with time. Different isolates of HIV strains showed a variability in the extent of sensitivity to neutralization by sera obtained from different HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784162     DOI: 10.1002/jmv.1890270103

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  2 in total

1.  Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers.

Authors:  C V Hanson; L Crawford-Miksza; H W Sheppard
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

Review 2.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.